Evidence map›Paper›PMID 38551395›Full record

ArticleImmunoHorizons2024

PD-1 Limits IL-2 Production and Thymic Regulatory T Cell Development.

Breanna Caruso, Benjamin R Weeder, Reid F Thompson, Amy E Moran

Open access · goldAbstract read
In one paragraph

Article in ImmunoHorizons, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Breanna CarusoCell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, OR.ORCID 0000-0002-1519-8131
Benjamin R WeederDepartment of Biomedical Engineering, Oregon Health and Science University, Portland, OR.
Reid F ThompsonDepartment of Biomedical Engineering, Oregon Health and Science University, Portland, OR.
Amy E MoranCell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, OR.ORCID 0000-0003-1952-7737
Oregon Health & Science University · US

Funding

Understanding how T cell intrinsic androgen receptor activity influences cell differentiation and dysfunctionR37CA263592 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Amy E Moran · 2021 to 2026
$3.2M
The Interplay Between PD-1 Blockade and T cell Development in the Context of Thymic Regeneration in Prostate CancerF31CA261058 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI CARUSO, BREANNA · 2021 to 2022
$93k
Quantifying and improving radiotherapy outcomes among VeteransIK2CX002049 · VA · PORTLAND VA MEDICAL CENTER · PI THOMPSON, REID · 2020 to 2025
–
CSRD VA IK2 CX002049NCI NIH HHS F31 CA261058NCI NIH HHS R37 CA263592
6 · The paper itself

Abstract

Inhibitory proteins, such as programmed cell death protein 1 (PD-1), have been studied extensively in peripheral T cell responses to foreign Ags, self-Ags, and neoantigens. Notably, these proteins are first expressed during T cell development in the thymus. Reports suggest that PD-1 limits regulatory T cell (Treg) development, but the mechanism by which PD-1 exerts this function remains unknown. The present study expands the evaluation of murine PD-1 and its ligands in the thymus, demonstrating that some of the highest expressers of PD-1 and programmed death-ligand 1 are agonist selected cells. Surprisingly, we reveal a selective role for PD-1 in regulating the developmental niche only for Tregs because other agonist selected cell populations, such as NK T cells, remain unchanged. We also ruled out PD-1 as a regulator of proliferation or cell death of agonist selected Tregs and further demonstrated that PD-1-deficient Tregs have reduced TCR signaling. Unexpectedly, the data suggest that PD-1-deficient thymocytes produce elevated levels of IL-2, a Treg niche-limiting cytokine. Collectively, these data suggest a novel role for PD-1 in regulating IL-2 production and the concurrent agonist selection of murine thymic Tregs. This observation has implications for the use of checkpoint blockade in the context of cancer and infection.

Indexed as

Interleukin-2Programmed Cell Death 1 ReceptorThymus GlandT-Lymphocytes, RegulatoryAnimalsCytokinesMiceCytokinesInterleukin-2Pdcd1 protein, mouseProgrammed Cell Death 1 Receptor

Identifiers

PMID38551395
PMCPMC10985057
OpenAlexW4393321216

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.